George Morrow, a director at Neurocrine Biosciences, Inc., has filed to sell 14,700 shares of common stock. This transaction, valued at approximately $2.15 million, is part of Morrow's strategy to exercise stock options and liquidate shares.

The filing, made on November 2, 2026, is significant as it reflects Morrow's ongoing financial maneuvers within the company. The sale is expected to take place shortly after the filing date.

Background

Neurocrine Biosciences, Inc. is a company classified under the SIC code 2836, which pertains to biological products (no diagnostic substances). The company is incorporated in Delaware and is publicly traded on NASDAQ under the SEC file number 000-22705. Its business address is located at 6027 Edgewood Bend Court, San Diego, CA 92130.

What the Filing Says

The filing indicates that Morrow acquired the shares through the exercise of stock options. The notice states, "The securities to be sold were and will be received upon the exercise of stock options over the next three months." The aggregate market value of the shares is reported as $2,147,670.

Impact

This sale may affect investor sentiment regarding Neurocrine Biosciences, particularly as it involves a key director. The biological products sector, which includes companies like Neurocrine, may see increased scrutiny as investors assess the implications of insider sales.

What's Next

The filing does not specify what happens next regarding Morrow's sale of shares or any further actions he may take.